logo
A mouse watching The Matrix changed what we know about our brains

A mouse watching The Matrix changed what we know about our brains

Independent10-04-2025

Scientists have constructed the most extensive functional brain map to date, charting the connections of 84,000 neurons as they transmit signals, thanks to a mouse that was shown clips from "The Matrix".
Researchers examined a fragment of the mouse's brain, approximately the size of a poppy seed, pinpointing neurons and tracing their communication pathways through branch-like fibres across 500 million junctions known as synapses.
The comprehensive dataset, which was published in the journal Nature on Wednesday, represents progress towards understanding the complexities of brain function. The data is presented in a 3D reconstruction with colour-coded brain circuitry and is accessible to scientists globally for further investigation, as well as for those with a general interest.
'It definitely inspires a sense of awe, just like looking at pictures of the galaxies,' said Forrest Collman of the Allen Institute for Brain Science in Seattle, one of the project's leading researchers. 'You get a sense of how complicated you are. We're looking at one tiny part ... of a mouse's brain and the beauty and complexity that you can see in these actual neurons and the hundreds of millions of connections between them.'
How we think, feel, see, talk and move are due to neurons, or nerve cells, in the brain – how they're activated and send messages to each other. Scientists have long known those signals move from one neuron along fibers called axons and dendrites, using synapses to jump to the next neuron. But there's less known about the networks of neurons that perform certain tasks and how disruptions of that wiring could play a role in Alzheimer's, autism or other disorders.
'You can make a thousand hypotheses about how brain cells might do their job but you can't test those hypotheses unless you know perhaps the most fundamental thing – how are those cells wired together,' said Allen Institute scientist Clay Reid, who helped pioneer electron microscopy to study neural connections.
With the new project, a global team of more than 150 researchers mapped neural connections that Collman compares to tangled pieces of spaghetti winding through part of the mouse brain responsible for vision.
The first step: Show a mouse video snippets of sci-fi movies, sports, animation and nature.
A team at Baylor College of Medicine did just that, using a mouse engineered with a gene that makes its neurons glow when they're active. The researchers used a laser-powered microscope to record how individual cells in the animal's visual cortex lit up as they processed the images flashing by.
Next, scientists at the Allen Institute analyzed that small piece of brain tissue, using a special tool to shave it into more than 25,000 layers, each far thinner than a human hair. With electron microscopes, they took nearly 100 million high-resolution images of those sections, illuminating those spaghetti-like fibers and painstakingly reassembling the data in 3D.
Finally, Princeton University scientists used artificial intelligence to trace all that wiring and 'paint each of the individual wires a different color so that we can identify them individually,' Collman explained.
They estimated that microscopic wiring, if laid out, would measure more than 3 miles (5 kilometers). Importantly, matching up all that anatomy with the activity in the mouse's brain as it watched movies allowed researchers to trace how the circuitry worked.
The Princeton researchers also created digital 3D copies of the data that other scientists can use in developing new studies.
Could this kind of mapping help scientists eventually find treatments for brain diseases? The researchers call it a foundational step, like how the Human Genome Project that provided the first gene mapping eventually led to gene-based treatments. Mapping a full mouse brain is one next goal.
'The technologies developed by this project will give us our first chance to really identify some kind of abnormal pattern of connectivity that gives rise to a disorder,' another of the project's leading researchers, Princeton neuroscientist and computer scientist Sebastian Seung, said in a statement.
The work 'marks a major leap forwards and offers an invaluable community resource for future discoveries,' wrote Harvard neuroscientists Mariela Petkova and Gregor Schuhknecht, who weren't involved in the project.
The huge and publicly shared data 'will help to unravel the complex neural networks underlying cognition and behavior,' they added.
The Machine Intelligence from Cortical Networks, or MICrONS, consortium was funded by the National Institutes of Health's BRAIN Initiative and IARPA, the Intelligence Advanced Research Projects Activity.
—-
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

8ft ambush shark 'more common' than thought on Welsh coast
8ft ambush shark 'more common' than thought on Welsh coast

North Wales Live

time3 hours ago

  • North Wales Live

8ft ambush shark 'more common' than thought on Welsh coast

An enigmatic species of shark known to be favour Welsh waters could be more abundant than previous suspected, scientists believe. The Angel shark, a large flat species resembling a stingray, is unique because it has evolved very differently to other types of shark. Previously only reliably spotted around the Canary Islands, catch evidence from Welsh fishermen has shown that Cardigan Bay is also a stronghold for this elusive and vulnerable species. The Welsh population had thought to be shrinking dramatically as a result of habitat damage and bycatch fishing, with one study indicating a 70% decline since 1970. A major conservation project was launched in the hope of saving a species that lingers on the sea floor, half-buried in sand and mud, waiting for prey to swim near them. They can grow up to 2.4m (8ft) long. However a new study, 'People & Nature', from the Zoological Society of London (ZSL) and Natural Resources Wales (NRW) suggests previous Angel shark counts were wide of the mark. Its authors believes changes to commercial fishing practices have seen fewer angel sharks caught. As the speckled, caramel-coloured sharks are masters of camouflage, finding them on the sea floor is virtually impossible. Instead, evidence from boat captains is the only reliable way the population can be assessed. It's now thought fishermen are catching fewer not because numbers are dwindling but because they are targeting different waters and using species-specific nets. To reach its conclusions, the ZSL-led study harnessed the expertise of Welsh fishing organisations. Co-author was Charlie Bartlett, a charter fisherman from Gwynedd, who said: 'I've spent over 50 years working along the Welsh coast, and over the years I've come to know these waters inside out. 'With their large, flat fins, Angel sharks are unlike any other shark we see here - and over the years I've been fortunate to encounter the species a number of times.' In the 40 years to 2020, some 1,642 Angel sharks were reported in Welsh coastal waters. A particular safe haven is in an area south of the Llŷn Peninsula. While they pose very little risk to humans, they have been known to bite when provoked. Literature analysis going back two centuries revealed they have a long maritime heritage in Wales. No fewer than 16 different names were uncovered, including Monkfish, Banjofish, Bafoon, Shovelnose and Devilfish. Its traditional Welsh name is Maelgi (Monkfish). The species has been adopted as the flagship species for marine conservation in Wales. Working with the Welsh Fishermen's Association (Cymdeithas Pysgotwyr) and Angling Cymru Sea Anglers, scientists interviewed 27 fishers about their operations between 1968 and 2019. It became clear modern practices involve fewer interactions with Angel sharks, leading to fewer sightings. Lead author Francesca Mason, a ZSL researcher at the Institute of Zoology's Ocean Predator Lab, said: 'There may be more Angel sharks swimming off the Welsh coast than we previously thought – we're just having a harder time spotting them. 'While this is a good sign if less Angel sharks are being caught accidentally, it also means we now need new ways to monitor them to build a more accurate picture of how these sharks are doing.' Instead of relying on chance sightings, scientists are now pinning their hopes on a novel technique involving environmental DNA (eDNA). This can build up in the shark's surroundings through the shedding of dead skin cells or blood loss from a wound. Already eDNA is being measured for Angel Shark Project: Wales, part of the wider work of Project SIARC (Sharks Inspiring Action and Research with Communities). Jake Davies, technical specialist for Project SIARC, said: 'With their excellent camouflage, one of the hardest challenges we face studying Angel sharks is simply finding them. eDNA allows us to study species without having to spot them. 'By studying eDNA in Cardigan and Carmarthen Bays, we've confirmed the presence of a range of native sharks, skates and rays - including Angel sharks - in these more turbulent waters where other monitoring methods aren't as effective. 'Fishers today may be less likely to come across Angel sharks than they were 50 years ago, but through combining this technique with local knowledge, we can continue building a stronger picture of their status and distribution along the Welsh coast.' The Angel shark work was supported by the On the Edge conservation charity, the National Lottery Heritage Fund, Welsh Government and the Welsh Government's Nature Networks Fund.

Common Sunday Dinner herb fights dementia, diabetes, heart disease and eczema
Common Sunday Dinner herb fights dementia, diabetes, heart disease and eczema

Daily Mirror

time13 hours ago

  • Daily Mirror

Common Sunday Dinner herb fights dementia, diabetes, heart disease and eczema

Many of us will be adding it to our Sunday Roast with meat, potatoes and carrots A herb popular in UK dishes and often served at Sunday Dinner has been linked to better brain health, reduced inflammation and improved immune function. Research suggests rosemary may even be able to help in the fight against Alzheimer's disease, the leading cause of dementia worldwide. Rosemary is often served with lamb and added to roast potatoes and carrots on Sundays. It is also a staple herb in Mediterranean meals. ‌ In one study, people who breathed in rosemary's scent performed better on memory tasks compared to those in an unscented environment. ‌ Dipa Kamdar, Senior Lecturer in Pharmacy Practice at Kingston University, said: " There are several mechanisms at play. For starters, rosemary stimulates blood circulation, including to the brain, helping deliver more oxygen and nutrients, which may improve mental clarity. It also has calming properties; some studies suggest its aroma can reduce anxiety and improve sleep. Lower stress can mean better focus and memory retention. "Rosemary contains compounds that interact with the brain's neurotransmitters. One such compound, 1,8-cineole, helps prevent the breakdown of acetylcholine, a brain chemical essential for learning and memory. By preserving acetylcholine, rosemary may help support cognitive performance, especially as we age." She added: " Rosemary is packed with antioxidants, which help protect brain cells from damage caused by oxidative stress – a major factor in cognitive decline. Rosemary is rich in phytochemicals, plant compounds with health-enhancing effects. One of the most powerful is carnosic acid, an antioxidant and anti-inflammatory agent that helps shield brain cells from harm, particularly from the kinds of damage linked to Alzheimer's disease." In a study this year. scientists found a version of carnosic acid appeared to improve memory, boosted the number of synapses (the connections between brain cells), and reduced harmful Alzheimer's related proteins like amyloid-beta and tau. The same compound could be used to treat type 2 diabetes, cardiovascular disease and Parkinson's disease. Dipa told The Conversation: " Rosemary's benefits could extend well beyond the brain. It's been used traditionally to ease digestion, relieve bloating and reduce inflammation. Compounds like rosmarinic acid and ursolic acid are known for their anti-inflammatory effects throughout the body. Rosemary may even benefit the skin – a review suggests it can help soothe acne and eczema, while carnosic acid may offer anti-ageing benefits by protecting skin from sun damage. ‌ " Rosemary oil also has antimicrobial properties, showing promise in food preservation and potential pharmaceutical applications by inhibiting the growth of bacteria and fungi. For most people, rosemary is safe when used in food, teas or aromatherapy. But concentrated doses or extracts can pose risks. Consuming large amounts may cause vomiting or, in rare cases, seizures – particularly in people with epilepsy. "There's also a theoretical risk of rosemary stimulating uterine contractions, so pregnant people should avoid high doses. Because rosemary can interact with some medications – such as blood thinners – it's best to check with a healthcare provider before taking large amounts in supplement form. "Rosemary is more than just a kitchen staple. It's a natural remedy with ancient roots and modern scientific backing. As research continues, particularly into breakthrough compounds like diAcCA, rosemary could play an exciting role in future treatments for Alzheimer's and other chronic conditions. "In the meantime, adding a little rosemary to your life – whether in a meal, a cup of tea, or a breath of its fragrant oil – could be a small step with big health benefits."

Alzheimer's blood test ‘can accurately pick up early symptoms'
Alzheimer's blood test ‘can accurately pick up early symptoms'

North Wales Chronicle

time3 days ago

  • North Wales Chronicle

Alzheimer's blood test ‘can accurately pick up early symptoms'

Experts from the Mayo Clinic in the US have provided further evidence that blood tests can work to accurately diagnose dementia, by examining two proteins in blood plasma. These proteins – amyloid beta 42/40 and p-tau217 – are associated with amyloid plaque build-up, which is a hallmark of Alzheimer's disease. Researchers found the blood test was highly accurate, with 95% sensitivity, which means it was 95% accurate in picking up people with memory problems, with very few cases missed. It was also 82% for specificity, which means it was also highly accurate in ruling out people without dementia. The study was carried out on more than 500 people in an outpatient memory clinic, meaning it is real-world data. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' he said. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. He added: 'This study shows how blood tests are making diagnosis of Alzheimer's disease quicker, easier and more accessible than ever before in a real-world setting. 'While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed. 'Currently diagnosis options in the UK are often slow, expensive and can be invasive, meaning thousands miss out on the benefits one can bring. 'It's great to see blood tests like this approved for clinical use in the US – we hope to see the same in the NHS, which is why we're part of the Blood Biomarker Challenge.' The Blood Biomarker Challenge is a multi-million-pound research programme supported by the Alzheimer's Society, Alzheimer's Research UK and the National Institute for Health and Care Research. Its goal is to bring blood tests for dementia diagnosis to the NHS by 2029. Dr Oakley said: 'Blood tests will be critical to accelerate diagnosis and give more people access to the care, support and treatments they desperately need faster than ever before. 'We must see long-term investment in the tools and workforce needed to ensure everyone living with dementia can get an early an accurate diagnosis, which is even more important with disease-modifying treatments on the horizon.' Dr Julia Dudley, head of research at Alzheimer's Research UK, said: 'We urgently need to improve how we diagnose dementia and it's great to see international research working towards this goal. 'Blood tests in this study look at p-tau217 and amyloid beta 42/40, and showed the tests offered high accuracy in confirming Alzheimer's disease. 'This study adds to the growing evidence that blood tests can detect the diseases that cause dementia in people with early memory and thinking problems. 'An important point to consider is that people taking part in research don't always reflect the full diversity of those affected by dementia, who might have additional conditions or other characteristics. 'That is why work is needed to understand whether these blood tests work in a real-world setting. 'In the UK, studies like the Blood Biomarker Challenge are helping to build this evidence. 'The study is testing blood tests, including p-tau217, in thousands of people from sites across the UK. 'This work will be a crucial part of making diagnosis easier and faster, which will bring us closer to a cure.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store